How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2026 · second_quarter · Q2
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
Source: Senate LDA
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Lower Costs, More Transparency Act of 2026
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822 Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act - provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37) H.R.9393 Lower Costs, More Transparency Act of 2026
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
Lower Health Care Premiums for All Americans Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
Preserving Patient Access to Long-Term Care Pharmacies Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
PBM Price Transparency and Accountability Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
Pharmacy Benefit Manager Transparency Act of 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.891, The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; RIN 0938-AV40, provisions related to coverage of anti-obesity medications in Medicare Part D and Medicaid.
Pharmacy Benefit Manager Transparency Act of 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.
H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.
S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.891, The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; RIN 0938-AV40, provisions related to coverage of anti-obesity medications in Medicare Part D and Medicaid.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
To provide for a limitation on availability of funds for Related Agencies, John F. Kennedy Center for the Performing Arts, Capital Repair and Restoration for fiscal year 2024.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.
To provide for a limitation on availability of funds for Related Agencies, John F. Kennedy Center for the Performing Arts, Capital Repair and Restoration for fiscal year 2024.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs
To provide for a limitation on availability of funds for Related Agencies, John F. Kennedy Center for the Performing Arts, Capital Repair and Restoration for fiscal year 2024.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
To provide for a limitation on availability of funds for Related Agencies, John F. Kennedy Center for the Performing Arts, Capital Repair and Restoration for fiscal year 2024.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.
S.891, The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; RIN 0938-AV40, provisions related to coverage of anti-obesity medications in Medicare Part D and Medicaid.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards
S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.
Seniors’ Access to Critical Medications Act of 2024
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
International Port Security Enforcement Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs
S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
S.891, The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; RIN 0938-AV40, provisions related to coverage of anti-obesity medications in Medicare Part D and Medicaid.
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards
To require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.10050: Pharmacist Audit & Compensation Transparency Act, a bill to require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.9096: Pharmacists Fight Back Act, a bill to establish pharmacy payment and reimbursement by PBMs; to amend Medicaid and to improve prescription drug transparency. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
H.R.10050: Pharmacist Audit & Compensation Transparency Act, a bill to require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.1339: Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Education on the efficacy and outreach of new obesity medications.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S.1339: Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Education on the efficacy and outreach of new obesity medications.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
H.R.9096: Pharmacists Fight Back Act, a bill to establish pharmacy payment and reimbursement by PBMs; to amend Medicaid and to improve prescription drug transparency. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
Pharmacy Benefit Manager Transparency Act of 2023
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
Pharmacy Benefit Manager Transparency Act of 2023
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.1339: Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Education on the efficacy and outreach of new obesity medications.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.1339: Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Education on the efficacy and outreach of new obesity medications.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S.1339: Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Education on the efficacy and outreach of new obesity medications.
H.R.10050: Pharmacist Audit & Compensation Transparency Act, a bill to require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
Health Care Prices Revealed and Information to Consumers Explained Transparency Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.3430: Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S.2973: Modernizing and Ensuring PBM Accountability Act - provisions related to PBM contracting, audits and disclosures. H.R.5526: Seniors Access to Critical Medications Act of 2023 provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec.302: Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: Telehealth Modernization Act of 2024, Section on Arrangements with Pharmacy Benefit Managers with Respect to Prescription 23 Drug Plans and MA-PD Plans.
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169: The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec. 302, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: "Telehealth Modernization Act of 2024", Sec. 202, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans.
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
Improving Mental Health and Wellness in Schools Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169: The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec. 302, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: "Telehealth Modernization Act of 2024", Sec. 202, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans.
Improving Mental Health and Wellness in Schools Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
Improving Mental Health and Wellness in Schools Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S.2973: Modernizing and Ensuring PBM Accountability Act - provisions related to PBM contracting, audits and disclosures. H.R.5526: Seniors Access to Critical Medications Act of 2023 provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec.302: Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: Telehealth Modernization Act of 2024, Section on Arrangements with Pharmacy Benefit Managers with Respect to Prescription 23 Drug Plans and MA-PD Plans.
Protecting Patients from Deceptive Health Plans Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
Financial Crimes Enforcement Network Improvements Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169: The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec. 302, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: "Telehealth Modernization Act of 2024", Sec. 202, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans.
Financial Crimes Enforcement Network Improvements Act
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S.2973: Modernizing and Ensuring PBM Accountability Act - provisions related to PBM contracting, audits and disclosures. H.R.5526: Seniors Access to Critical Medications Act of 2023 provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec.302: Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: Telehealth Modernization Act of 2024, Section on Arrangements with Pharmacy Benefit Managers with Respect to Prescription 23 Drug Plans and MA-PD Plans.
Hotel Advertising Transparency Act of 2022
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169: The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec. 302, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: "Telehealth Modernization Act of 2024", Sec. 202, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans.
Hotel Advertising Transparency Act of 2022
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S.2973: Modernizing and Ensuring PBM Accountability Act - provisions related to PBM contracting, audits and disclosures. H.R.5526: Seniors Access to Critical Medications Act of 2023 provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec.302: Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: Telehealth Modernization Act of 2024, Section on Arrangements with Pharmacy Benefit Managers with Respect to Prescription 23 Drug Plans and MA-PD Plans.
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
A bill to establish an Inspector General of the National Institutes of Health.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S.2973: Modernizing and Ensuring PBM Accountability Act - provisions related to PBM contracting, audits and disclosures. H.R.5526: Seniors Access to Critical Medications Act of 2023 provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec.302: Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: Telehealth Modernization Act of 2024, Section on Arrangements with Pharmacy Benefit Managers with Respect to Prescription 23 Drug Plans and MA-PD Plans.
A bill to establish an Inspector General of the National Institutes of Health.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
A bill to establish an Inspector General of the National Institutes of Health.
Client: PRIME THERAPEUTICS · Firm: PRIME THERAPEUTICS
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169: The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec. 302, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: "Telehealth Modernization Act of 2024", Sec. 202, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans.
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2026 · first_quarter · Q1
H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.
H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2025 · fourth_quarter · Q4
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards S. 3159/H.R. 5031 Preserving Patient Access to Long Term Care Pharmacies Act provision designed to ensure continued access to essential medications and pharmacy services for seniors in long- term care facilities by establishing a temporary supply fee for pharmacies. H.R. 9096 Pharmacists Fight Back Act legislation to establish pharmacy payment, transparency requirements and reimbursement by pharmacy benefits managers in federal programs S.3345 - PBM Price Transparency and Accountability Act -provisions reforming PBM practices in Medicare in Medicaid including delinking, a ban on Medicaid spread pricing, transparency and audit rights H.R. 6703, the Lower Health Care Premiums for All Americans Act -provisions addressing PBM practices in Medicare and Medicaid
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2025 · third_quarter · Q3
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs
S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 5378 (118th Congress), Lower Cost, More Transparency Act H.R. 4231 Treat and Reduce Obesity Act-provisions related to coverage of obesity medications in Medicare H.R. 4317, PBM Reform Act of 2025 legislation on PBM reform in Medicare and pharmacy access standards
Tariffs on pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2025 · second_quarter · Q2
H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.
S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.
Tariffs on pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2025 · first_quarter · Q1
H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.
S.891, The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. Medicare and Medicaid Programs: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; RIN 0938-AV40, provisions related to coverage of anti-obesity medications in Medicare Part D and Medicaid.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2024 · fourth_quarter · Q4
H.R.9096: Pharmacists Fight Back Act, a bill to establish pharmacy payment and reimbursement by PBMs; to amend Medicaid and to improve prescription drug transparency. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
H.R.10050: Pharmacist Audit & Compensation Transparency Act, a bill to require the Secretary of Health and Human Services to conduct a study on pharmacy benefit manager audit practices. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Division E Healthcare of H.R.10445, Further Continuing Appropriation and Disaster Relief Supplemental Appropriations Act of 2025: provisions regulation PBMs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2024 · third_quarter · Q3
S.3430: Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S.2973: Modernizing and Ensuring PBM Accountability Act - provisions related to PBM contracting, audits and disclosures. H.R.5526: Seniors Access to Critical Medications Act of 2023 provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec.302: Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: Telehealth Modernization Act of 2024, Section on Arrangements with Pharmacy Benefit Managers with Respect to Prescription 23 Drug Plans and MA-PD Plans.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2024 · second_quarter · Q2
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S.4349: A bill to require private health plans to provide for secure electronic transmission of prior authorization requests for prescription drugs.
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169: The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices. Sec. 302, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans, of H.R. 8261, Preserving Telehealth, Hospital, and Ambulance Access Act. H.R.7623: "Telehealth Modernization Act of 2024", Sec. 202, Arrangements with Pharmacy Benefit Managers with Respect to Prescription Drug Plans and MA-PD Plans.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2024 · first_quarter · Q1
S.3430: "Better Mental Healthcare, Lower Cost Drugs & Extenders Act," provisions related to PBMs and pharmacy contracting. S.2973: "Modernizing and Ensuring PBM Accountability Act," provisions related to PBM contracting, audits and disclosures. H.R.5526: "Seniors Access to Critical Medications Act of 2023," provisions clarifying Medicare so that delivery of medicines through various methods or by allowing a family member or caregiver to pick up medication on behalf of a patient does not violate the Stark Law and does fall within the scope of Stark's IOAS exception. H.R.7512: "Real-Time Benefit Tool Implementation Act," legislation to ensure implementation of real-time benefit tools under part D of the Medicare program. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 "The Inflation Reduction Act," provisions related to changes in Medicare Part D and government negotiation of drug prices. S.2305: "Biosimilars Red Tape Elimination Act," provisions relating improving the requirements for making a determination of interchangeability of a biological product and its reference product.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2023 · fourth_quarter · Q4
S 1339, Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. H.R. 3682 of the 117th Congress Improving Transparency to Lower Drugs Costs Act of 2021-provisions related to public disclosure of drug rebate and other data. Transparency in Coverage Final Rule (CMS-9915-F) provisions related to machine readable drug files. S. 3548 A bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R. 5378 Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S. 1542/H.R. 6283 The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms.
S. 3430, Better Mental Healthcare, Lower Cost Drugs & Extenders Act-provisions related to PBMs and pharmacy contracting. S. 2973 Modernizing and Ensuring PBM Accountability Act -provisions related to PBM contracting, audits and disclosures. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. H.R. 5461 Ensuring Access to Lower Cost Medicines for Seniors Act of 2023-provisions related to cost-sharing for generics and biosimilars in Medicare Part D. S. 2436 Neighborhood Options for Patients Buying Medicines (NO PBMs) Act-provisions related to pharmacy contracting under Medicare. H.R. 2880 Protecting Patients Against PBM Abuses Act-provisions regulating PBM reimbursement in Part D contracts. H.R. 5386 Cutting Copays Act provisions relating to changes to co-pays for Medicare Part D low-income beneficiaries. H.R. 4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program. H.R. 5372 Expanding Seniors Access to Lower Cost Medicines Act of 2023-to amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. H.R. 5393 The Transparency and Fairness for Pharmacists Act-provisions relating to pharmacy assessment in Medicare Part D. H.R. 5385 Medicare PBM Accountability Act; to amend Title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D. H.R. 1352, Increasing Access to Biosimilars Act of 2023-provisions related to a demonstration project providing additional provider payments for providers of biosimilars. Implementation of H.R. 5376 (117th Congress)/P.L. 117-169 The Inflation Reduction Act-provisions related to changes in Medicare Part D and government negotiation of drug prices.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2023 · third_quarter · Q3
H.R. 5372: Expanding Seniors Access and Lost Cost Medicines Act of 2023, provisions to set drug price cost-sharing. H.R. 5385: Medicare PBM Accountability Act, provisions related to PBM reporting requirements. H.R. 5386: Cutting Coupons Act, provisions related to cost-sharing requirements for low-income Medicare beneficiaries. H.R. 3284: Providers & Payers COMPETE Act, provisions related to consolidation. S. 2973: Modernizing and Ensuring PBM Accountability Act, provisions related to PBM regulation.
S. 954: Affordable Insulin Now Act of 2023, provisions related to cost-sharing for insulin. S. 1269: INSULIN Act of 2023, provisions related to cost-sharing for insulin. H.R. 5378: The Lower Costs, More Transparency Act, provisions related to PBM transparency. S. 2305: Biosimilar Red Tape Elimination Act, provisions related to addressing biosimilar interchangeability. H.R. 4507: Transparency in Coverage Act of 2023, provisions related to PBM transparency. H.R. 4527: Health DATA Act provisions related to plan fiduciaries access to data. H.R. 5378: The Lower Costs, More Transparency Act, Sections 105, 106, 109, 110, 202, 401, 402 and 403, provisions related to PBM transparency and disclosure. S. 127: PBM Transparency Act of 2023, provisions related to PBM disclosure and contracting arrangements. S. 1339: PBM Reform Act, provisions related to PBM disclosure and contracting arrangements.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2023 · second_quarter · Q2
PBM Transparency-Issues concerning PBM reporting of rebates and payments through the pharmaceutical supply chain. S. 127, The Pharmacy Benefit Manager Transparency Act of 2023," provisions related to the Federal Trade Commission regulation of PBMs. H.R. 4011, Timely Access to Clinical Treatment (TACT) Act of 2023, provisions on pharmacy access standards. Issues related to cost-sharing for insulin and other therapies in the commercial market. S. 1339, the Pharmacy Benefit Manager Reform Act provisions related to PBM disclosure, fee pass through and fee structures. H.R. 3862, Improving Transparency to Lower Drug Cost Act of 2021 (117th Congress)-provisions related to PBM transparency and disclosure. H.R. 3561, The PATIENT Act, provisions related to disclosure of drug price concessions and highly-rebated drugs. H.R. 37999, the CHOICE Act, potential amendments related to PBM pharmacy contracting practices. Issues related to patient cost-sharing and drug coupons. H.R. 3281/H.R. 2681, The Transparence PRICE Act, issues related to disclosure of drug price concessions. H.R. 2679, Pharmacy Benefit Manager Accountability Act, provisions related to client disclosure of drug price concessions particularly coupon use.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2023 · first_quarter · Q1
PBM Transparency-issues concerning PBM reporting of rebates and payments through the pharmaceutical supply chain. 117th Congress, H.R. 7666, Restoring Hope for Mental Health and Well Being Act of 2022, Title VI, Section 602 Oversight of Pharmacy Benefit Managers, provisions relating to PBM audits and disclosures in the commercial market. S. 127, The Pharmacy Benefit Manager Transparency Act of 2023, provisions related to the Federal Trade Commission regulation of PBMs. H.R. 1352, Increasing Access to Biosimilars, provisions related to expanding access to biosimilars. S. 113, Prescription Pricing for the People Act, provisions related to an FTC study of PBMs.
Implementation of the Inflation Reduction Act of 2022, P.L. 117-169 provisions on Medicare Part D modernization and drug price negotiation. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. CMS proposed rule (CMS-4201-P) Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly provisions related to the definition of Gross Covered Prescription Drug Costs.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2022 · fourth_quarter · Q4
Draft version of the "INSULIN Act:" provisions on cost-sharing, utilization management and rebates for insulin. H.R. 7666: "The Restoring Hope for Mental Health and Well-Being Act of 2022," Title VI, Sec. 602, Oversight of Pharmacy Benefit Manager Services. Senate Omnibus as Amendment #6552 to H.R. 2617 relating to the Consolidated Appropriations Act, 2023, - possible provisions related to pharmacy benefit managers.
Draft version of the "INSULIN Act:" provisions on cost-sharing, utilization management and rebates for insulin. H.R. 7666: "The Restoring Hope for Mental Health and Well-Being Act of 2022," Title VI, Sec. 602, Oversight of Pharmacy Benefit Manager Services. Senate Omnibus as Amendment #6552 to H.R. 2617 relating to the Consolidated Appropriations Act, 2023, - possible provisions related to pharmacy benefit managers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2022 · third_quarter · Q3
Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees." Outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed and Final Rules, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program. H.R. 19/S. 2164: "Lower Cost, More Cures Act," provisions on drug prices and Part D cost-sharing and Part D reform. H.R. 5376/P.L. 117-169: "Inflation Reduction Act"/"Build Back Better Act," provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule. S. 3700/H.R. 6833: "Affordable Insulin Now Act," provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans. Draft versions of the "INSULIN Act," provisions on cost-sharing, utilization management and rebates for insulin. H.R. 8487: "Seniors Timely Access to Care Act," general education on prior authorization.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2022 · second_quarter · Q2
Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed and Final Rules, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program;" HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs; S. 3700/H.R. 6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans; draft versions of the INSULIN Act, provisions on cost-sharing, utilization management and rebates for insulin.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2022 · first_quarter · Q1
Implementation of S2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D and CMS-4192-P, Proposed Rule, Medicare Program: Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Program; HR19 / S2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR3-Elijah E. Cummings Lower Drug Costs Act Now,-provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; HR 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs; S3700 / HR6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2021 · fourth_quarter · Q4
Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164 - Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3 - Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, H.R. 3684/ P.L. 117-58, Infrastructure Investment Act, provisions related to the repeal of a rule repealing the safeharbor for drug rebate; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; Medicaid and Medicare drug pricing; Medicare Part D reform, repeal of the rebate rule and audit/transparency provisions on PBMs.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2021 · third_quarter · Q3
Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act,--provisions related to the implementation of Every Prescription Conveyed Securely Act, Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees,; outreach on pharmacy direct and indirect remuneration in Medicare Part D; H.R. 19/S. 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, Prescription Drug Pricing Reduction Act of 2020,--provisions related to PBMs, Part D cost-sharing, inflation rebates and drug pricing; H.R. 2846, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021-formulary tiering of biosimilars and generics in Medicare Part D; . H.R.5237 -"To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes--provisions related to drug price negotiation, PBM audits, pharmacy disclosures and payments and drug rebates; S. 2327, Seniors Prescription Drug Relief Act, provisions allowing Medicare beneficiaries to spread their cost-sharing across a plan year; H.R. 3684, Infrastructure Investment Act,--provisions related to the repeal of a rule repealing the safe harbor for drug rebate; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2021 · second_quarter · Q2
Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act,; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees,; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, Prescription Drug Pricing Reduction Act of 2020,-provisions related to PBMs, Part D cost-sharing, inflation rebates and drug pricing; H.R. 2759, Pharmacy and Medically Underserved Areas Enhancement Act, To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacists services; H.R. 3831, To amend title XVII of the Social Security Act to provide for certain rules regarding the treatment of eligible retirement plans in determining the eligibility of individuals for premium and cost-sharing subsidies in Medicare Part D; S. 1773, Prescription Drug Pricing Dashboard Act,-provisions related to a CMS dashboards on prescription drug spending; H.R. 2846, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021-formulary tiering of biosimilars and generics in Medicare Part D; potential suspension of pharmacy audits during the public health emergency; and Part D reform and modernization
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2021 · first_quarter · Q1
Implementation of S.2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees, outreach on pharmacy direct and indirect remuneration in Medicare Part D. 116th Congress HR 19, Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing. 116th Congress HR 3, Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals.
116th Congress S.1895, The Lower Health Care Costs Act. Sec.306 Health Plan Oversight of PBMs. 116th Congress HR 19, Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing. 116th Congress HR 3, Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2020 · fourth_quarter · Q4
Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. Presidential Executive Order on lowering Prices for Patients by Eliminating Kickbacks to Middlemen, issued July 24, 2020 requiring the completion of rulemaking to exclude from safe harbor protection drug rebates in Medicare Part D; and, Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees. Presidential Executive Order on Lowering Drug Prices by Putting America First, Issued Sept 13, 2020 creating a Most Favored Nation Price for drugs in Medicare Part D. Outreach on pharmacy direct and indirect remuneration in Medicare Part D. H.R.19: Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing. H.R.3: Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2020 · third_quarter · Q3
H.R. 6800: HEROES Act, Sec. 30205 Requiring Coverage Under Medicare PDPs and MA-PD Plans Without the Imposition of Cost Sharing or Utilization Management Requirements of Drugs Intended to Treat COVID-During Certain Emergencies. S. 4469: COVID-19 Treatment Coverage Act Sec. 6 Coverage of COVID-19 Drugs at no cost sharing under Medicare prescription drug plans. Value-based contracting and Medicaid Best Price. Implementation of Sec. 20003 the SUPPORT Act for Patients and Communities Act, provisions related to the implementation of Every Prescription Conveyed Securely Act. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, to amend Title XVIII of the Social Security Act to allow for the offering of additional prescription drug plans under Medicare Part D. Presidential Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen, issued July 24, 2020 requiring the completion of rulemaking to exclude from safe harbor protection drug rebates in Medicare Part D. Presidential Executive Order on Lowering Drug Prices by Putting America First, issued September 13, 2020 creating a Most Favored Nation Price for drugs in Medicare Part B and Part D. Outreach on pharmacy direct and indirect remuneration in Medicare Part D and on real time benefit tools.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2020 · second_quarter · Q2
S.1895: The Lower Health Care Costs Act, Sec. 306, Health Plan Oversight of PBMs. CURES 2.0: provisions related to value-based care. HR 19/S.3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesign of the Medicare Part D benefit. HR 3: Elijah E. Cummings Lower Drugs Cost Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. Issues related to the drug supply chain country of origin and impact on the availability of drugs in the USA.
HR 3: Elijah E. Cummings Lower Drugs Cost Now Act,-provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. HR 19/S 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesign of the Medicare Part D benefit. HR 6739: Ensuring Seniors Access to COVID Treatments Act. HR 6800: HEROES Act, Sec. 30205 Requiring Coverage Under Medicare PDPS and MA-PD Plans, Without the Imposition of Cost Sharing or Utilization Management Requirements, of Drugs Intended to Treat Covid - During Certain Emergencies. Value-based contracting and Medicaid Best Price. Sec. 3714 of P.L. 116-136 The CARES Act, related to requiring that Medicare Part D and C plan beneficiaries have access to 90-day prescriptions at the beneficiarys request. S. 2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 -provisions on Medicare Part D and PBMs. Outreach on pharmacy direct and indirect remuneration in Medicare Part D and real time benefit tools. Implementation of Sec. 2003 SUPPORT for Patients and Communities Act, provisions related to implementation of Every Prescription Conveyed Securely Act.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2020 · first_quarter · Q1
S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. H.R. 3 Elijah E. Cummings Lower Drugs Cost Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129 The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesign of the Medicare Part D benefit. H.R. 5304, legislation to amend title IIVII of the Public Health Service Act to require health plan oversight of pharmacy benefit managers.
H.R.3: Elijah E. Cummings Lower Drugs Cost Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, Reforms drug pricing by promoting greater competition and redesign of the Medicare Part D benefit. H.R. 5304: legislation to amend title IIVII of the Public Health Service Act to require health plan oversight of pharmacy benefit managers. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part. Draft legislation Patient Affordability, Value and Efficiency Act, provisions encouraging wider use of value-based contracting. Outreach and education on pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Provisions of Sec. 3714 of P.L. 116-136: The CARES Act, related to requiring that Medicare Part D and C plan beneficiaries have access to 90-day prescriptions at the beneficiaries request. Implementation of P.L. 115-271, Sec. 2003, SUPPORT For Patients and Communities Act, provisions related to implementation of Every Prescription Conveyed Securely Act,
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2019 · fourth_quarter · Q4
H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2119: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. H.R. 5304: legislation to amend title XXVII of the Public Health Service Act to require health plan oversight of pharmacy benefit manager services.
H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2199: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part D. S. 2543: The Prescription Drug Pricing Reduction Act, legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drug. Provisions related to inflation protection and PBM transparency. Medicare Advantage and Part D Drug Pricing Final Rule, (CMS-4180-F), provisions related to pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Outreach and education on pharmacy DIR in Medicare Part D. H.R. 2115: Public Disclosure of Drug Discounts and Real-time Beneficiary Drugs Costs Act, provisions requiring HHS to publish information online about discounts under Medicare Advantage and Part D and requirements related to real-time benefits tool implementation. H.R. 1791: The Payment Commission Data Act of 2019, legislation that would require government commission to receive rebate and other data from PBMs/Part D plans.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2019 · third_quarter · 3A
HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2019 · third_quarter · Q3
S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. S.2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, -Legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drugs. Provisions related to inflation protection provisions and PBM transparency. S.2247: Phair Relief Act, Provisions related to pharmacy DIR. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment. CMS Proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," (CMS-4180-P)-provisions related to pharmacy Direct and Indirect Negotiation.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2019 · second_quarter · Q2
Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Request for information: "HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs," provisions affecting market competition for prescription drugs and the drug supply chain. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act, eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1497: Health Care Price Check Act of 2019, requires Medicare and insurance companies to make available an online tool and a toll-free # for beneficiaries to inquire about the cost, for that specific consumer, of any services, procedure or product including prescription drugs. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2019 · first_quarter · Q1
Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain.
S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act Pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act. S 64: Preserve Access to Affordable Generics and Biosimilars Act - Prohibits brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act - eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act H.R. 1264 and H.R. 1781 and S. 801 - Provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2018 · fourth_quarter · Q4
Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain.
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2018 · third_quarter · Q3
Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines (became HR 6; awaiting President's signature). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-263). H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2018 · second_quarter · Q2
H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2018 · first_quarter · Q1
H.R.749/S.974: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2017 · fourth_quarter · Q4
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act--issues relating to Medicare Part D cash price disclosure. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes"(House only). Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. H.R.4169: Protecting Seniors Access to Proper Care Act of 2017 --provisions focused on prescriber enrollment relief.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2017 · third_quarter · Q3
H.R.749/S.974: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. H.R.2026: Pharmaceutical Information Exchange Act--provisions relating to payer access to pharma data. H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2017 · second_quarter · Q2
S. 778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
H.R.749: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster.H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition.H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R. 1245: Affordable and Safe Prescription Drug Importation Act--issues relating to noninterference and workability. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. H.R.2026: Pharmaceutical Information Exchange Act--provisions relating to payer access to pharma data. H.R.2051: The FAST Generics Act--provisions that expedite market access for generics.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2017 · first_quarter · Q1
S.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act - restrictions on payor quallity programs in Medicare Part D. Draft bill to amend title XVIII of the Social Security Act to provide for greater access to drug cost information for Medicare beneficiaries by preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies - issues related to noninterference in Medicare Part D. Counter efforts to elimination of the Medicare Part D non-interference clause. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act - Issues relating to Medicare Part D cash price disclosure. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. Draft bill to amend part A of title XVIII of the Social Security Act to provide greater access to information regarding the items and services furnished to the individual under parts A and B of the Medicare program and greater context regarding the medication regimen of the individual - issues relating to use of Medicare data.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2016 · fourth_quarter · Q4
Potential future guidance on DIR: Direct and Indirect Renumeration for Pharmacies. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.244: "MAC Transparency Act," educating on how MAC pricing helps control costs for consumers. H.R.793/S.1190: "Ensuring Seniors Access to Local Pharmacies Act of 2015," importance of pharmacy networks in reducing costs. H.R.1600: "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. Drug pricing in general. H.R.5951 and S.3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.
H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2016 · third_quarter · Q3
S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-ins, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. HR.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. S.1945: Senate HELP mental health reform package, Mental Health Reform Act of 2016, mental health parity treatment of step therapy and prior-authorization. S.2615: Increasing Competition in Pharmaceuticals Act, support increasing generic availability. H.R.6: The 21st Century Cures Act and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600: The Patients' Access to Treatment Act, educating on the importance of step therapy to ensuring optimal therapy access and cost control. H.R.2841: the FAST Generics Act. S.3056: the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S.2700: Workforce Authorities Modernization Act, Section 11, Biological Product Innovation - treatment of USP compendia in approving biologics and biosimilars. Role of PBMs in Mylan pricing before Congressional hearings/investigation of Mylan. Drug pricing in general. H.R.6043 and S.3335, "Fair Accountability and Innovative Research Drug Pricing Act of 2016".
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2016 · second_quarter · Q2
S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-ins, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. HR.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. S.1945: Senate HELP mental health reform package, Mental Health Reform Act of 2016, mental health parity treatment of step therapy and prior-authorization. S.2615: Increasing Competition in Pharmaceuticals Act, support increasing generic availability. H.R.6: The 21st Century Cures Act and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600: The Patients' Access to Treatment Act, educating on the importance of step therapy to ensuring optimal therapy access and cost control. H.R.2841: the FAST Generics Act. S.3056: the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. S.2700: Workforce Authorities Modernization Act, Section 11, Biological Product Innovation - treatment of USP compendia in approving biologics and biosimilars.
PRIME THERAPEUTICS via PRIME THERAPEUTICS
2016 · first_quarter · Q1
S.524, Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs). H.R.4784, Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680, A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes.
S.524 "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). H.R.244, "MAC Transparency Act," educating on how MAC pricing helps control costs for consumers. H.R.793/S.1190, "Ensuring Seniors Access to Local Pharmacies Act of 2015," importance of pharmacy networks in reducing costs. H.R.1600, "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. S.480/H.R.1725, "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding.
Tariffs on pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1339: Pharmacy Benefit Manager Reform Act-provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. H.R.5378: Lower Costs, More Transparency Act provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: The Delinking Revenue from Unfair Gouging (DRUG) Act-provisions dictating PBM contracting terms. S.2305: The Biosimilar Red Tape Elimination Act-legislation addressing the standards for interoperability for biosimilars and requirements for switching studies. Education on the efficacy and outreach of new obesity medications.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1339: "Pharmacy Benefit Manager Reform Act," provisions related to disclosure, audits and PBM contracting. Proposed amendments to S.1339 creating a default spread pricing option with options to elect pass-through payments for PBM compensation. S.3548: "Health Care Prices Revealed and Information to Consumers Explained Transparency Act," a bill to amend the Public Health Services Act to provide for hospital and insurer price transparency. H.R.5378: "Lower Costs, More Transparency Act," provisions related to PBM transparency and disclosure requirements. S.1542/H.R.6283: "The Delinking Revenue from Unfair Gouging (DRUG) Act," provisions dictating PBM contracting terms. S.127: Pharmacy Benefit Manager Transparency Act of 2023, a bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation. Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration. S. 1967, Patients Before Middlemen Act, provisions governing how PBM compensation and use of metrics in determining drug rebates. S. 2052, A bill to amend title XVIII of the Social Security Act to enforce any willing pharmacy requirements and establish safeguards to ensure patient access to pharmacists in Medicare Part D and for other purposes. S. 2543 (116th Congress, Prescription Drug Pricing Reform Act of 2019 provisions on drug pricing disclosures. Issues related to utilization of real-time benefit checks.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Education on the value of biosimilars; H.R. 19/S. 2164: "Lower Cost, More Cures Act," provisions on drug prices and Part D cost-sharing and Part D reform. H.R. 5376/P.L. 117-169: "Build Back Better Act"/"Inflation Reduction Act," provisions relating to insulin cost-sharing; repeal of the rebate rule. S. 3700/H.R. 6833: "Affordable Insulin Now Act," provisions related to cost-sharing for insulin in Medicare and private plans. Draft versions of the "INSULIN Act," provisions on cost-sharing, utilization management and rebates for insulin. S. 4293: "The Pharmacy Benefit Manager Transparency Act of 2022," provisions on the FTC regulation of PBMs. S. 1388: "Prescription Pricing for the People Act of 2021," provisions related to an FTC study of PBMs; provisions related to restrictions on spread pricing in the commercial market for PBMs. H.R. 7666: "The Restoring Hope for Mental Health and Well-Being Act of 2022," Title VI, Sec. 602, Oversight of Pharmacy Benefit Manager Services.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Education on the value of biosimilars; HR 19/S 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs; S. 3700/H.R. 6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and 116th Congress H.R. 2069; draft versions of the INSULIN Act, provisions on cost-sharing, utilization management and rebates for insulin; S. 4293 The Pharmacy Benefit Manager Transparency Act of 2022, provisions on the FTC regulation of PBMs and S. 1388, Prescription Pricing for the People Act of 2021, provisions related to an FTC study of PBMs; provisions related to restrictions on spread pricing in the commercial market for PBMs, and HR. 4390, Protect 430(b) Act of 2021, provisions related to the treatment of 340(b) drug discount program by PBMs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior and on the important role PBMs play in holding down drug costs; HR19 /S2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR3-Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; HR5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs; S3700 /HR6833, Affordable Insulin Now Act, provisions related to cost-sharing for insulin in Medicare and private plans and mental health issues as they relate to prescription drug plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior and on the important role PBMs play in holding down drug costs; Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees; outreach on pharmacy direct and indirect remuneration in Medicare Part D; HR 19/S 2164 - Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; HR 3 - Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, H.R. 3684/ P.L. 117-58, Infrastructure Investment Act, provisions related to the repeal of a rule repealing the safeharbor for drug rebate; H.R. 5376, Build Back Better Act, provisions relating to insulin cost-sharing; repeal of the rebate rule and audit/transparency provisions on PBMs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs; 116th Congress H.R. 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now,--provisions establishing drug pricing and Part D cost sharing; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,--provisions related to PBM contracting; education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs ; 116th Congress HR 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress HR 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; S. 464/H.R. 2163, Safe Step Act,-Amending ERISA to specify exceptions for medication step therapy; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,-provisions related to PBM contracting; S. 164/P.S. 117-8 Advancing Education on Biosimilars Act of 2021-provisions related to an FDA campaign for prescriber education on biosimilars; S. 415/P.L. 117-9, A bill to clarify the meaning of a new chemical entity by the FDA; ; potential suspension of pharmacy audits during the public health emergency and reform of the orphan drug act; measures to combat pharma patent thickets
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1895: The Lower Health Care Costs Act, Sec. 306, Health Plan Oversight of PBMs. H.R.133: Consolidated Appropriations Act, 2021, provisions related to PBM transparency and disclosure. H.R.19: Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing. H.R.3: Elijah E. Cummings Lower Drug Costs Act Now, provisions establishing drug pricing and Part D cost sharing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. S.2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, -Legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drugs. Provisions related to inflation protection provisions and PBM transparency. S.2247: Phair Relief Act, Provisions related to pharmacy DIR. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment. CMS Proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," (CMS-4180-P)-provisions related to pharmacy Direct and Indirect Negotiation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain.
S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act, eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1497: Health Care Price Check Act of 2019, requires Medicare and insurance companies to make available an online tool and a toll-free # for beneficiaries to inquire about the cost, for that specific consumer, of any services, procedure or product including prescription drugs. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Request for information: "HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs," provisions affecting market competition for prescription drugs and the drug supply chain. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act Pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act. S 64: Preserve Access to Affordable Generics and Biosimilars Act - Prohibits brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act - eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act H.R. 1264 and H.R. 1781 and S. 801 - Provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines(became HR 6, which is awaiting President's signature). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-263). H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines (became HR 6, awaiting President's signature). Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. S.2553: "Know the Lowest Price Act," --"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-262). H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. H.R.6641: True Cost-sharing of Seniors Drugs Transparency Act provisions related to pharmacy gag clause. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare.
S.2460/H.R.3528: Every Prescription Conveyed Securely Act - provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines (became HR 6, awaiting President's signature).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse.
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. S.2553: "Know the Lowest Price Act," --"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries Provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration.
S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines. S.2460/H.R.3528: Every Prescription Conveyed Securely Act - provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act--issues relating to Medicare Part D cash price disclosure. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes"(House only). Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. S.2553: "Know the Lowest Price Act," --"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices.
S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines. S.2460/H.R.3528: Every Prescription Conveyed Securely Act - provisions requiring electronic prescribing of controlled substances in Medicare Part D (House only).
S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines. H.R.3528: Every Prescription Conveyed Securely Act - provisions requiring electronic prescribing of controlled substances in Medicare Part D (House only).
S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).
H.R.749/S.974: "Lower Drugs Costs Through Competition Act,"--increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. H.R.2212/S.974: CREATES Act--provisions related to removing barriers to generic competition. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. S.778 Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. H.R.2026: Pharmaceutical Information Exchange Act--provisions relating to payer access to pharma data. H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. S.637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act--issues relating to Medicare Part D cash price disclosure. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--provisions related to the stability of the exchanges. H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes"(House only)
H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only).
S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines. H.R.3528: Every Prescription Conveyed Securely Act - provisions requiring electronic prescribing of controlled substances in Medicare Part D (House only).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act--provisions restricting payer quality payment programs in Medicare Part D. Draft bill to amend title XVIII of the Social Security Act to provide for greater access to drug cost information for Medicare beneficiaries by preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies--issues related to Medicare non-interference. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act--issues relating to noninterference and workability. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S. 1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes. Provisions related do drug coverage in Medicare and Medicaid. H.R.1316: The Prescription Drug Price Transparency Act -Issues related to ensuring the continuity of MAC pricing. S.637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act--issues relating to Medicare Part D cash price disclosure. H.R.1628: The American Health Care Act of 2017 and The Better Care Reconciliation Act--Provisions related to the stability of the exchanges. Draft bill to amend part A of title XVIII of the Social Security Act to provider greater access to information regarding the items and services furnished to the individual under parts A and B of the Medicare program and greater context regarding the medication regimen of the individual, issues relating to use of Medicare data.
H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act --issues relating to noninterference and workability. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S.1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes; provisions related do drug coverage in Medicare and Medicaid. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. S.778:Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
HR 749: Lower Drug Costs Through Competition Act - increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. HR 1121: Preexisting Conditions Protect Act of 2017 - issues relating to market stability in exchanges. S. 191: Patient Freedom Act of 2017 - issues relating to market stability in exchanges. S. 469/H.R. 1245: Affordable and Safe Prescription Drug Importation Act. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 771/H.R. 1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. H.R. 1628: The American Health Care Act of 2017 - issues related to market stabilization. S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
S. 778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.2615: Increasing Competition in Pharmaceuticals Act, support increasing generic availability. H.R.6/P.L. 114-252: The 21st Century Cures Act and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600: The Patients' Access to Treatment Act, educating on the importance of step therapy to ensuring optimal therapy access and cost control. H.R.2841: the FAST Generics Act. S.3056: the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. Drug pricing in general. H.R.6043 and S.3335, "Fair Accountability and Innovative Research Drug Pricing Act of 2016".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Potential future guidance on DIR: Direct and Indirect Renumeration for Pharmacies. S.524: "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). S.480/H.R.1725: "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.244: "MAC Transparency Act," educating on how MAC pricing helps control costs for consumers. H.R.793/S.1190: "Ensuring Seniors Access to Local Pharmacies Act of 2015," importance of pharmacy networks in reducing costs. H.R.1600: "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. Drug pricing in general. H.R.5951 and S.3308, Improving Transparency and Accuracy in Medicare Part D Spending Act.
S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act.
Potential future guidance on DIR: Direct and Indirect Renumeration for Pharmacies. S.524: "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). S.480/H.R.1725: "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.244: "MAC Transparency Act," educating on how MAC pricing helps control costs for consumers. H.R.793/S.1190: "Ensuring Seniors Access to Local Pharmacies Act of 2015," importance of pharmacy networks in reducing costs. H.R.1600: "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.480/H.R.1725, "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding.
S.524, "Comprehensive Addiction and Recovery Act," focused on Prescription Drug Management Plans (PDMPs). S.1945, Senate HELP mental health reform package, "Mental Health Reform Act of 2016," mental health parity treatment of step therapy and prior-authorization. S.2615, "Increasing Competition in Pharmaceuticals Act," support increasing generic availability. H.R.6, "The 21st Century Cures Act" and Senate companions, ensuring no new barriers to generic and biosimilar market entry. Generic Drug User Fee Act Reauthorization, support increasing generic availability. H.R.1600, "The Patients' Access to Treatment Act," educating on the importance of step therapy to ensuring optimal therapy access and cost control. S.480/H.R.1725, "National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015," educating on the importance of PDMPs and the need for federal funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE